When are topical calcineurin inhibitors recommended for morphea?

Morphea causes areas of inflammation followed by skin thickening, firmness, or changes in colour. A topical medicine is more likely to be discussed when the process is limited to the skin surface. Deeper, widespread, rapidly changing, or function-limiting disease may require a different plan, because a cream or ointment may not reach the tissues involved. The word active can refer to a lesion with ongoing inflammatory signs, such as a lilac-coloured edge, rather than an area that has become inactive and firm.

Your dermatologist may examine the colour, border, texture, depth, and position of each patch before choosing treatment. Apply the prescribed product only to the areas and schedule provided. Use gentle skin care and avoid vigorous rubbing over firm or fragile skin. Keep photographs or notes of changes between visits if your clinician recommends this; they can help show whether a border is expanding or inflammation is settling. Do not assume that a lack of discomfort means the condition is inactive.

Contact your dermatologist if a patch enlarges, becomes more purple or tender, develops marked thickening, or restricts movement near a joint. Seek prompt review for changes on the face, near an eye, or over a body area where tightening affects function. New widespread patches, ulcers, or signs of infection also need assessment because they may change the treatment approach.

Ask whether your morphea is superficial or deep, whether it appears active, how progress will be monitored, and what finding would prompt a change from topical treatment.